CA2678125C - Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride - Google Patents

Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride Download PDF

Info

Publication number
CA2678125C
CA2678125C CA2678125A CA2678125A CA2678125C CA 2678125 C CA2678125 C CA 2678125C CA 2678125 A CA2678125 A CA 2678125A CA 2678125 A CA2678125 A CA 2678125A CA 2678125 C CA2678125 C CA 2678125C
Authority
CA
Canada
Prior art keywords
erythro
crystalline forms
tetrahydrobiopterin dihydrochloride
tetrahydrobiopterin
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2678125A
Other languages
French (fr)
Other versions
CA2678125A1 (en
Inventor
Rudolf Moser
Viola Groehn
Thomas Egger
Fritz Blatter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck et Cie
Original Assignee
Merck et Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2678125(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck et Cie filed Critical Merck et Cie
Publication of CA2678125A1 publication Critical patent/CA2678125A1/en
Application granted granted Critical
Publication of CA2678125C publication Critical patent/CA2678125C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are suitable for solid formulations.
CA2678125A 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride Active CA2678125C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52037703P 2003-11-17 2003-11-17
US60/520,377 2003-11-17
CA002545968A CA2545968C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002545968A Division CA2545968C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride

Publications (2)

Publication Number Publication Date
CA2678125A1 CA2678125A1 (en) 2005-07-21
CA2678125C true CA2678125C (en) 2014-10-14

Family

ID=34748739

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2678124A Active CA2678124C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
CA2678125A Active CA2678125C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
CA002545968A Active CA2545968C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
CA2678165A Active CA2678165C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2678124A Active CA2678124C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA002545968A Active CA2545968C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
CA2678165A Active CA2678165C (en) 2003-11-17 2004-11-17 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride

Country Status (10)

Country Link
US (3) US7727987B2 (en)
EP (1) EP1687308B1 (en)
JP (2) JP2007536210A (en)
CN (1) CN1894251B (en)
AU (1) AU2004311544A1 (en)
CA (4) CA2678124C (en)
ES (1) ES2755334T3 (en)
HK (1) HK1103294A1 (en)
RU (1) RU2434870C2 (en)
WO (1) WO2005065018A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029533T2 (en) 2003-11-17 2017-03-28 Biomarin Pharm Inc Treatment of phenylketonuria with bh4
AU2004311544A1 (en) 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
US8003126B2 (en) * 2004-11-17 2011-08-23 Biomarin Pharmaceutical Inc. Stable tablet formulation
PL1869048T3 (en) * 2005-04-14 2009-05-29 Shiratori Pharmaceutical Co Ltd Method for producing alpha form crystals of sapropterin hydrochloride
DK2139485T3 (en) 2007-04-11 2013-01-21 Biomarin Pharm Inc METHODS OF ADMINISTRATION OF TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASUREMENT
CL2009000007A1 (en) 2008-01-07 2010-02-19 Biomarin Pharm Inc Method to prepare biopterin by hydrolysis of diacetylbiopterin in the presence of a base in a biphasic mixture of water and an organic solvent immiscible in water at a pH of 10.
CN102443006B (en) 2010-10-13 2016-02-24 因华生技制药股份有限公司 (6R) preparation method of-Tetrahydrobiopterin hydrochloride
TWI526437B (en) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 Crystalline forms of cabazitaxel
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
PL2926805T3 (en) * 2014-03-31 2016-12-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2016117663A1 (en) 2015-01-21 2016-07-28 味の素株式会社 Precipitation accelerator and precipitation method in which same is used
JP7148532B2 (en) 2016-11-29 2022-10-05 ピーティーシー セラピューティクス エムピー，インコーポレイテッド Polymorphs of Sepipterin
CA3043502A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphs of sepiapterin and salts thereof
BR112020003865A8 (en) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS INCLUDING SEPIAPTERIN AND THEIR USES
CN108033963A (en) * 2017-12-29 2018-05-15 天津凯莱英制药有限公司 R-THBP dihydrochloride crystal form B and preparation method thereof
JP2021525729A (en) 2018-05-30 2021-09-27 ピーティーシー セラピューティクス エムピー，インコーポレイテッド Sepiapterin Methods for Increasing Plasma Exposure
AU2022350669A1 (en) * 2021-09-23 2024-04-04 Fritz Blatter Egfr inhibitor polymorph forms

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5883691A (en) * 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd 1',2'-diacyl-(6r,s)-5,6,7,8-tetrahydro-l-biopterin and its preparation
JPS5925323A (en) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 Depression disease parkinsonism therapy made from pterin derivative
JPS60178887A (en) 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd Preparation of 5,6,7,8-tetrahydro-l-biopterin
JPS60204786A (en) * 1984-03-29 1985-10-16 Univ Nagoya Synthesis of (6r)-tetrahydrobiopterin and its relating substance
JPS61172877A (en) * 1985-01-28 1986-08-04 Shiratori Seiyaku Kk Production of (6r)-tetrahydro-l-biopterin
JPS61172876A (en) * 1985-01-28 1986-08-04 Shiratori Seiyaku Kk Production of (6r)-tetrahydro-l-biopterin
US4713454A (en) 1985-01-28 1987-12-15 Shiratori Pharmaceutical Co., Ltd. Preparation process of (6R)-tetrahydro-L-biopterin
US4785571A (en) * 1988-02-11 1988-11-22 Beck Gilbert F Fish hook with live bait holder
AU623978B2 (en) * 1989-02-28 1992-05-28 Nisshin Flour Milling Co. Ltd. Stabilized fat-soluble vitamin compositions
ATE189770T1 (en) * 1992-10-14 2000-03-15 Nippon Shinyaku Co Ltd METHOD FOR SHIFTING A CRYSTAL STATE
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
BR0209918A (en) * 2001-05-22 2004-03-30 Pfizer Prod Inc Crystalline forms of azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
AU2004311544A1 (en) 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
AR047541A1 (en) * 2004-02-13 2006-01-25 Sandoz Ag PHOSPHATE OF 5 - [[4- [2-METHYL-2-PYRIDINYL-AMINO-ETOXI] PHENYL] METHYL] -2,4 THYZOLIDINADION (ROSIGLITAZONE) AND ITS POLYMORPHIC FORMS
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
UA91546C2 (en) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP5063600B2 (en) * 2005-08-29 2012-10-31 サノフイ−アベンテイス・ユー・エス・エルエルシー Novel crystal forms of pyridazino [4,5-B] indole derivatives
CA2617816A1 (en) * 2005-09-13 2007-03-22 Sicor Inc. Process for the synthesis of rocuronium bromide
US20090239946A1 (en) * 2006-09-28 2009-09-24 Mckeown Arlene E Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitors chelate complexes
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
US20080102186A1 (en) * 2006-10-31 2008-05-01 Daniel Perlman Gelled vegetable oil condiment utilizing glycerol and hydrophilic microparticulate silicon dioxide
PE20081506A1 (en) * 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
JP2009189170A (en) * 2008-02-07 2009-08-20 Panasonic Corp Energy converter and semiconductor device and switch control method for the energy converter

Also Published As

Publication number Publication date
RU2434870C2 (en) 2011-11-27
HK1103294A1 (en) 2007-12-14
WO2005065018A3 (en) 2005-10-20
US20100099685A1 (en) 2010-04-22
US7727987B2 (en) 2010-06-01
JP2007536210A (en) 2007-12-13
CA2678124C (en) 2014-10-07
US8344139B2 (en) 2013-01-01
US20060035900A1 (en) 2006-02-16
CA2545968A1 (en) 2005-07-21
CN1894251A (en) 2007-01-10
CN1894251B (en) 2011-06-29
CA2545968C (en) 2010-03-09
JP2011162568A (en) 2011-08-25
CA2678125A1 (en) 2005-07-21
RU2006121341A (en) 2008-01-10
ES2755334T3 (en) 2020-04-22
WO2005065018A2 (en) 2005-07-21
US20100240667A1 (en) 2010-09-23
EP1687308A2 (en) 2006-08-09
CA2678165C (en) 2013-11-05
AU2004311544A1 (en) 2005-07-21
US8318745B2 (en) 2012-11-27
CA2678165A1 (en) 2005-07-21
CA2678124A1 (en) 2005-07-21
EP1687308B1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
CA2678125C (en) Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2004113292A3 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
MX2007005221A (en) Ascomycin crystalline forms and preparation thereof.
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
TW200720232A (en) Crystalline solid forms of tigecycline and methods of preparing same
AU2003224652A1 (en) Methods for forming articles having very small channels therethrough, and such articles, and methods of using such articles
EP1499590B8 (en) Piperidine derivatives as potassium channel blockers
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
AU2002357882A1 (en) Small-molecule inhibitors of interleukin-2
PT1467735E (en) Polymorphs of clopidogrel hydrogensulfate
AU2002246728A1 (en) Carboline derivatives
AU2003228770A1 (en) Substituted pyrazolopyrimidines
AU2002249890A1 (en) Carboline derivatives
AU2003290592A1 (en) Antitumor benzoylsulfonamides
AU2003231833A1 (en) Cross-linked glycopeptide-cephalosporin antibiotics
TW200508233A (en) Chk-1 inhibitors
WO2004026267A3 (en) Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
GB0308201D0 (en) Novel compounds
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
AU2003252467A1 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
AU2003245880A1 (en) Process for the preparation of thioalkylamine derivatives
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate

Legal Events

Date Code Title Description
EEER Examination request